We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$143M
1-Year Est. Return
102.52%
This Fund
S&P 500
This Quarter
Est. Return
+24.34%
1 Year Est. Return
+102.52%
3 Year Est. Return
+167.58%
5 Year Est. Return
+215.85%
10 Year Est. Return
+1,289.38%
AUM
$2.08B
AUM Growth
-$1.3B
(-39%)
Cap. Flow
-$1.79B
Cap. Flow
% of AUM
-86.14%
Top 10 Holdings %
Top 10 Hldgs %
46.37%
Holding
64
New
8
Increased
12
Reduced
35
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$41.5M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$23.2M |
| 3 |
Celldex Therapeutics
CLDX
|
+$21.6M |
| 4 |
Pfizer
PFE
|
+$19.8M |
| 5 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$19.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$151M |
| 2 |
Viatris
VTRS
|
+$125M |
| 3 |
Boston Scientific
BSX
|
+$123M |
| 4 |
AGN
Allergan plc
AGN
|
+$123M |
| 5 |
Edwards Lifesciences
EW
|
+$118M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.29% |
| 2 | Miscellaneous | 11.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$187B
| $170M | 8.16% |
2,696,687
-234,270
| -8% | -$14M |
|
|
2
Amgen
AMGN
$236B
| $144M | 6.91% |
1,282,992
+382,473
| +42% | +$41.5M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $123M | 5.92% |
1,597,272
+9,400
| +0.6% | +$659K |
|
|
4
Incyte
INCY
$25.7B
| $96.3M | 4.63% |
2,524,684
-5,116,673
| -67% | -$151M |
|
5
Vertex Pharmaceuticals
VRTX
$138B
| $93.7M | 4.51% |
1,235,755
-1,290,259
| -51% | -$103M |
|
6
Innoviva
INVA
$1.54B
| $79.4M | 3.82% |
2,412,117
-1,518,276
| -39% | -$47.2M |
|
7
Biogen
BIIB
$32.6B
| $68.9M | 3.32% |
286,200
+2,900
| +1% | +$649K |
|
|
NPSP
8
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $66.3M | 3.19% |
2,083,128
-219,300
| -10% | -$5.03M |
|
|
IMGN
9
DELISTED
Immunogen Inc
IMGN
| $62.2M | 2.99% |
3,652,893
-2,766,091
| -43% | -$48.6M |
|
|
MDVN
10
DELISTED
MEDIVATION, INC.
MDVN
| $60.8M | 2.92% |
2,027,058
-3,407,288
| -63% | -$97.3M |
|
11
Thermo Fisher Scientific
TMO
$227B
| $58.4M | 2.81% |
633,400
+125,600
| +25% | +$11.4M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $57.4M | 2.76% |
494,508
-17,600
| -3% | -$1.93M |
|
13
Ironwood Pharmaceuticals
IRWD
$704M
| $56.8M | 2.73% |
5,731,019
-346,497
| -6% | -$3.4M |
|
|
ARIA
14
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $55.4M | 2.66% |
3,008,541
-2,284,141
| -43% | -$44.3M |
|
15
Regeneron Pharmaceuticals
REGN
$85.2B
| $54.8M | 2.63% |
175,000
-99,666
| -36% | -$26.2M |
|
16
BioMarin Pharmaceuticals
BMRN
$12.9B
| $52.1M | 2.51% |
721,906
-1,251,158
| -63% | -$83.2M |
|
|
SHPG
17
DELISTED
Shire pic
SHPG
| $49.3M | 2.37% |
411,586
-80,747
| -16% | -$8.92M |
|
18
Halozyme
HALO
$12.5B
| $48.4M | 2.33% |
4,386,362
+1,125,400
| +35% | +$9.38M |
|
19
Merck
MRK
$371B
| $47.7M | 2.3% |
1,050,870
-1,648,075
| -61% | -$75.2M |
|
|
20
Viatris
VTRS
$19.4B
| $45.3M | 2.18% |
1,186,782
-3,543,221
| -75% | -$125M |
|
|
AGN
21
DELISTED
Allergan Inc
AGN
| $39.3M | 1.89% |
433,986
-613,791
| -59% | -$55.1M |
|
|
22
Celldex Therapeutics
CLDX
$3.12B
| $33.5M | 1.61% |
+62,968
| New | +$21.6M |
|
|
GEVA
23
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $29.9M | 1.44% |
+470,950
| New | +$23.2M |
|
|
AGN
24
DELISTED
Allergan plc
AGN
| $29.2M | 1.4% |
202,650
-923,016
| -82% | -$123M |
|
25
Perrigo
PRGO
$2.07B
| $28.5M | 1.37% |
231,185
-362,540
| -61% | -$45.2M |
|
Similar funds
ICMP
JPT
SL
PWM
BOM
AVA
FPC
ACP
Sectoral Asset Management's Q3 2013 Portfolio in Review
As of Q3 2013, Sectoral Asset Management held 64 positions worth $2.08B, down 39% from $3.38B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Sectoral Asset Management withdrew a net $1.79B in Q3 2013, closing 9 positions and reducing 35 holdings. Its most notable exit was Edwards Lifesciences, an estimated $118M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Miscellaneous.
Against the trend, Sectoral Asset Management opened a new position in SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $29.9M.
- Sectoral Asset Management's largest Q3 2013 buy was SYNAGEVA BIOPHARMA CORP COM STK (DE): 470,950 shares worth $29.9M.
- Sectoral Asset Management added most to Amgen in Q3 2013, an estimated $41.5M increase.
- Sectoral Asset Management's biggest Q3 2013 reduction was Incyte, cutting an estimated $151M.
- Sectoral Asset Management fully exited Edwards Lifesciences in Q3 2013, selling an estimated $118M.
- Sectoral Asset Management's ten largest holdings make up 46% of its $2.08B portfolio in Q3 2013.
- Sectoral Asset Management opened 8 new positions and closed 9 in Q3 2013.
- Sectoral Asset Management's portfolio value fell 39% quarter-over-quarter to $2.08B.
Based on Sectoral Asset Management's 13F filing for Q3 2013, filed 13 Nov 2013.